secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2026-04-21T23:59:59+00:00
Accession:  0001628280-26-026259
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn presents preclinical data at AACR: FHD-909 combo shows complete regression and immune memory
--------------------------------------------------------------------------------

- FHD-909 (SMARCA2 inhibitor) plus anti-PD-1 achieved complete tumor regression and immune memory in preclinical SMARCA4-mutant models.
- Selective CBP degrader FHT-171 showed strong anti-tumor activity and favorable tolerability in heavily pretreated ER+ breast cancer PDX models.
- Selective EP300 degrader outperformed clinical benchmark inobrodib in multiple myeloma models, including pomalidomide-resistant xenografts.
- Cereblon-based selective ARID1B degraders achieved robust degradation with potential for oral bioavailability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828026026259/0001628280-26-026259-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828026026259/fhtx-20260421.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-026259

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer